Clinical Trials Browser

Multiple Myeloma

NCT01665794 2025-12-22

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

25 enrolled

Plasma cell

Multiple Myeloma

NCT02362035 2025-12-11

KEYNOTE145

Phase 1/2 Completed

161 enrolled 29 charts

LymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Phase 1/2 Completed

34 enrolled 18 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

NCT07102706 2025-08-05

Phase I Trial of GR1803 Injection in Patients With RRMM

Phase 1/2 Completed

76 enrolled

Plasma cell

Multiple Myeloma

NCT03548207 2025-07-30

CARTITUDE-1

Phase 1/2 Completed

126 enrolled 36 charts 1 FDA

Plasma cell

Multiple Myeloma

NCT01864018 2025-07-24

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Phase 1/2 Completed

87 enrolled 13 charts

Plasma cell

Amyloidosis, Multiple Myeloma

NCT06055075 2025-07-14

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

19 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT00112827 2025-06-06

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

Phase 1/2 Completed

54 enrolled 13 charts

Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

NCT04083534 2025-05-30

First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)

Phase 1/2 Completed

43 enrolled

Plasma cell

Multiple Myeloma

NCT03417284 2025-05-01

Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation

Phase 1/2 Completed

62 enrolled 10 charts

Plasma cell

Multiple Myeloma

NCT02649790 2025-03-19

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Phase 1/2 Completed

277 enrolled

GastrointestinalMyeloidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Myelodysplastic Syndromes, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT03544281 2025-03-18

DREAMM 6

Phase 1/2 Completed

153 enrolled 91 charts

Plasma cell

Multiple Myeloma

NCT03732703 2025-02-14

MyDRUG

Phase 1/2 Completed

103 enrolled

Plasma cell

Multiple Myeloma

NCT03773107 2025-01-13

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

Phase 1/2 Completed

12 enrolled 19 charts

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03997968 2024-12-24

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Phase 1/2 Completed

169 enrolled

BreastGastrointestinalGynecologicHead & NeckLymphoidPlasma cellSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Lymphoma, Mantle-Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01755975 2024-11-07

Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

Phase 1/2 Completed

49 enrolled 15 charts

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT01827137 2024-09-19

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Phase 1/2 Completed

20 enrolled 9 charts

GenitourinaryPlasma cell

Multiple Myeloma, Wilms Tumor

NCT02633059 2024-09-19

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Phase 1/2 Completed

33 enrolled 26 charts

Plasma cell

Chromosome 17 deletion, Multiple Myeloma

NCT05199337 2024-09-19

Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis

Phase 1/2 Completed

18 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT03267888 2024-09-04

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

25 enrolled 11 charts

Plasma cell

Multiple Myeloma

NCT01183949 2024-08-02

Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

Phase 1/2 Completed

18 enrolled

LymphoidPlasma cell

Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT03194867 2024-06-14

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Phase 1/2 Completed

109 enrolled 27 charts

Plasma cell

Multiple Myeloma

NCT01063907 2024-04-25

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Phase 1/2 Completed

95 enrolled 13 charts

LymphoidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Blood Protein Disorders, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias, Leukemia, B-Cell, Neoplasms, Plasma Cell

NCT03848845 2024-04-09

DREAMM 4

Phase 1/2 Completed

41 enrolled 57 charts

Plasma cell

Multiple Myeloma

NCT02119468 2024-03-15

Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Phase 1/2 Completed

32 enrolled 15 charts

Plasma cell

Multiple Myeloma

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Phase 1/2 Completed

45 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT02685826 2023-10-06

A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma

Phase 1/2 Completed

56 enrolled 38 charts

Plasma cell

Multiple Myeloma

NCT04445701 2023-08-22

Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Completed

10 enrolled

Plasma cell

Multiple Myeloma

NCT02204241 2023-07-03

CCD

Phase 1/2 Completed

36 enrolled

Plasma cell

Disease, Multiple Myeloma

NCT01348919 2023-06-28

Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

11 enrolled 15 charts

Plasma cell

Multiple Myeloma, Neoplasms

NCT00566098 2023-05-26

Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma

Phase 1/2 Completed

26 enrolled 13 charts

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02751255 2023-04-28

DARA/ATRA

Phase 1/2 Completed

60 enrolled

Plasma cell

Multiple Myeloma

NCT01794520 2023-04-10

Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

117 enrolled 29 charts

Plasma cell

Multiple Myeloma

NCT01040026 2023-04-04

Expanded Natural Killer (NK) Cells for Multiple Myeloma Study

Phase 1/2 Completed

10 enrolled

Plasma cell

Multiple Myeloma

NCT03312530 2023-02-28

A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma

Phase 1/2 Completed

49 enrolled 24 charts

Plasma cell

Multiple Myeloma

NCT03439280 2023-02-24

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Phase 1/2 Completed

50 enrolled 26 charts

Plasma cell

Multiple Myeloma, Recurrence

NCT02186834 2023-01-04

Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

Phase 1/2 Completed

28 enrolled 10 charts

Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01242267 2023-01-03

Thal/Mel/Vel

Phase 1/2 Completed

29 enrolled 13 charts

Plasma cell

Multiple Myeloma

NCT01177397 2022-12-13

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

Phase 1/2 Completed

226 enrolled 42 charts

CNSGastrointestinalLymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse

NCT01947140 2022-11-23

PDX+Romi

Phase 1/2 Completed

57 enrolled

DermatologicLymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03236792 2022-09-29

Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis

Phase 1/2 Completed

28 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

NCT01677858 2022-09-23

CHAMPION 1

Phase 1/2 Completed

116 enrolled 28 charts

Plasma cell

Multiple Myeloma

NCT00784823 2022-08-11

Mel-Vel

Phase 1/2 Completed

32 enrolled 8 charts

Plasma cell

Multiple Myeloma

NCT02384083 2022-07-27

Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients

Phase 1/2 Completed

47 enrolled

Plasma cell

Multiple Myeloma

NCT03678259 2022-03-25

124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis

Phase 1/2 Completed

57 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT01502085 2022-01-21

RZD

Phase 1/2 Completed

25 enrolled 5 charts

Plasma cell

Multiple Myeloma

NCT02145403 2022-01-03

Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

Phase 1/2 Completed

53 enrolled 17 charts

LymphoidOther hematologic neoplasmPlasma cell

Graft vs Host Disease, Leukemia, Lymphoma, Multiple Myeloma, Recurrence, Hematologic Neoplasms

NCT01421186 2021-11-16

A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Completed

91 enrolled 19 charts

Plasma cell

Multiple Myeloma

NCT00421525 2021-08-16

Phase I/II Study of hLL1 in Multiple Myeloma

Phase 1/2 Completed

25 enrolled

Plasma cell

Multiple Myeloma, Plasmacytoma

Clinical Trials

ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

KEYNOTE145

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Phase I Trial of GR1803 Injection in Patients With RRMM

CARTITUDE-1

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)

Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

DREAMM 6

MyDRUG

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

DREAMM 4

Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma

Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

CCD

Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma

DARA/ATRA

Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

Expanded Natural Killer (NK) Cells for Multiple Myeloma Study

A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

Thal/Mel/Vel

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

PDX+Romi

Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis

CHAMPION 1

Mel-Vel

Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients

124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis

RZD

Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma

Phase I/II Study of hLL1 in Multiple Myeloma